Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

471
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
471
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

480
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
480
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

631
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
631
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

449
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
449
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

438
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
438
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

945
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
945

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vitamin K Deficiency and Thrombophilia in Pregnancy: A Fine Balance Between Bleeding and Thrombus Formation-Insights from a Narrative Review.

International journal of molecular sciences·2026
Same author

Romanian National Study on the Epidemiology of Inflammatory Bowel Diseases.

Journal of gastrointestinal and liver diseases : JGLD·2026
Same author

EEG-Derived Entropy Monitoring During Propofol Sedation for ERCP: Sedation Profiles, Age-Related Effects, and Implications for Procedure-Specific Target Ranges.

Medicina (Kaunas, Lithuania)·2026
Same author

Chrononutrition Behaviors and BMI Change During the Transition to University Life in Young Adults: A Prospective Study.

Nutrients·2026
Same author

Mortality Attributable to Hepatitis B and C in Italy, Romania, and Spain, 2022 Estimates.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

EUS point shear-wave elastography: A novel approach for noninvasive liver fibrosis assessment.

Endoscopic ultrasound·2026

Related Experiment Video

Updated: Jan 13, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.9K

AI-Guided Multi-Omic Microbiome Modulation Improves Clinical and Inflammatory Outcomes in Refractory IBD: A

Raluca Lupusoru1,2,3, Lavinia Cristina Moleriu1, Ruxandra Mare3,4,5

  • 1Department III, Functional Science, Discipline of Medical Informatics and Biostatistics, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.

International Journal of Molecular Sciences
|January 10, 2026
PubMed
Summary

Personalized microbiome modulation using AI significantly improved inflammatory bowel disease (IBD) symptoms and inflammation markers. This AI-guided approach targeted gut bacteria and nutrient deficiencies for better patient outcomes.

Keywords:
artificial intelligence–guided therapygut microbiome modulationimmunometabolisminflammatory bowel disease (IBD)microbiome–immune interactionsmulti-omicspersonalized medicineshort-chain fatty acid–producing bacteria

More Related Videos

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.3K
Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

8.7K

Related Experiment Videos

Last Updated: Jan 13, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.9K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.3K
Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

8.7K

Area of Science:

  • Gastroenterology
  • Microbiome Research
  • Artificial Intelligence in Medicine

Background:

  • Inflammatory bowel disease (IBD) presents management challenges, especially in refractory cases.
  • Gut microbiome alterations are increasingly linked to IBD persistence and inflammation.
  • Current treatments often fail to address underlying microbial and metabolic imbalances.

Purpose of the Study:

  • To evaluate a three-month, AI-guided, multi-omic personalized microbiome modulation program for treatment-refractory IBD.
  • To assess the impact of individualized interventions on clinical outcomes, inflammatory markers, and gut microbial composition.
  • To determine if a personalized, multi-omic approach can achieve clinically meaningful improvements in IBD patients.

Main Methods:

  • Adults with treatment-refractory IBD underwent a three-month AI-guided program.
  • Data integration included stool metagenomics, blood biomarkers, and clinical information.
  • Interventions comprised dietary changes, synbiotics, antimicrobials, and micronutrient correction.

Main Results:

  • Significant reductions in stool frequency, urgency, and rectal bleeding were observed.
  • Over 70% of participants reported substantial overall improvement.
  • Marked normalization of inflammatory biomarkers (hs-CRP, fecal calprotectin) in over 85% of cases.
  • Improvement in micronutrient deficiencies and significant increases in beneficial bacteria (e.g., F. prausnitzii, B. longum, A. muciniphila).

Conclusions:

  • Personalized, multi-omic microbiome modulation shows promise for managing refractory IBD.
  • The AI-guided approach effectively targeted microbial, metabolic, and immune imbalances.
  • Further validation through randomized controlled studies is warranted to confirm these encouraging findings.